Arienna M. Hyseni

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.

A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.

Journal: Skin health and disease

Published: February 28, 2025

Correction: The UPDATE trial (UVB Phototherapy in Dermatology for Atopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.

Correction: The UPDATE trial (UVB Phototherapy in Dermatology for Atopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.

Journal: Trials

Published: February 18, 2025

Implementing Federated Analysis Using DataSHIELD in the DREAM TO TREAT Atopic Dermatitis Registries Collaboration.

Implementing Federated Analysis Using DataSHIELD in the DREAM TO TREAT Atopic Dermatitis Registries Collaboration.

Journal: The Journal of investigative dermatology

Published: December 09, 2024

Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.

Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.

Journal: The British journal of dermatology

Published: March 25, 2024

The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.

The UPDATE trial (UVB Phototherapy in Dermatology for ATopic Eczema): study protocol for a randomized controlled trial of narrowband UVB with optimal topical therapy versus optimal topical therapy in patients with atopic eczema.

Journal: Trials

Published: March 11, 2024

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.

Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types.

Journal: JAAD international

Published: September 18, 2022

Work ability and quality of working life in atopic dermatitis patients treated with dupilumab.

Work ability and quality of working life in atopic dermatitis patients treated with dupilumab.

Journal: The Journal of dermatology

Published: March 05, 2021

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.

A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 31, 2018

Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.

Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.

Journal: Journal of thrombosis and thrombolysis

Published: March 20, 2017

The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.

The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban or rivaroxaban.

Journal: Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing

Published: December 10, 2016

Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans.

Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans.

Journal: Thrombosis and haemostasis

Published: September 26, 2013

Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa.

Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa.

Journal: Journal of thrombosis and haemostasis : JTH

Published: May 28, 2013

Showing 1-12 of 12

Last Updated: 09/26/2026